vs
Side-by-side financial comparison of American Homes 4 Rent (AMH) and Bio-Techne (TECH). Click either name above to swap in a different company.
American Homes 4 Rent is the larger business by last-quarter revenue ($455.0M vs $295.9M, roughly 1.5× Bio-Techne). American Homes 4 Rent runs the higher net margin — 31.7% vs 12.8%, a 18.9% gap on every dollar of revenue. On growth, American Homes 4 Rent posted the faster year-over-year revenue change (4.2% vs -6.4%). Over the past eight quarters, Bio-Techne's revenue compounded faster (4.2% CAGR vs 3.6%).
American Homes 4 RentAMHEarnings & Financial Report
American Homes 4 Rent, doing business as AMH, is a real estate investment trust based in Las Vegas, Nevada, that invests in single-family rental homes. As of December 31, 2019, the company owned 52,552 homes in 22 states. Its largest concentrations are in Atlanta, Dallas-Fort Worth, and Charlotte, North Carolina.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
AMH vs TECH — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $455.0M | $295.9M |
| Net Profit | $144.3M | $38.0M |
| Gross Margin | — | 64.6% |
| Operating Margin | — | 18.4% |
| Net Margin | 31.7% | 12.8% |
| Revenue YoY | 4.2% | -6.4% |
| Net Profit YoY | 0.3% | 68.3% |
| EPS (diluted) | $0.33 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $455.0M | $295.9M | ||
| Q3 25 | $478.5M | — | ||
| Q2 25 | $457.5M | $317.0M | ||
| Q1 25 | $459.3M | $316.2M | ||
| Q4 24 | $436.6M | $297.0M | ||
| Q3 24 | $445.1M | $289.5M | ||
| Q2 24 | $423.5M | $306.1M | ||
| Q1 24 | $423.6M | $303.4M |
| Q4 25 | $144.3M | $38.0M | ||
| Q3 25 | $116.8M | — | ||
| Q2 25 | $123.6M | $-17.7M | ||
| Q1 25 | $128.7M | $22.6M | ||
| Q4 24 | $143.9M | $34.9M | ||
| Q3 24 | $87.6M | $33.6M | ||
| Q2 24 | $108.5M | $40.6M | ||
| Q1 24 | $128.1M | $49.1M |
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% | ||
| Q1 24 | — | 67.4% |
| Q4 25 | — | 18.4% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -7.5% | ||
| Q1 25 | — | 12.2% | ||
| Q4 24 | — | 16.0% | ||
| Q3 24 | — | 13.8% | ||
| Q2 24 | — | 15.0% | ||
| Q1 24 | — | 22.1% |
| Q4 25 | 31.7% | 12.8% | ||
| Q3 25 | 24.4% | — | ||
| Q2 25 | 27.0% | -5.6% | ||
| Q1 25 | 28.0% | 7.1% | ||
| Q4 24 | 33.0% | 11.7% | ||
| Q3 24 | 19.7% | 11.6% | ||
| Q2 24 | 25.6% | 13.3% | ||
| Q1 24 | 30.2% | 16.2% |
| Q4 25 | $0.33 | $0.24 | ||
| Q3 25 | $0.27 | — | ||
| Q2 25 | $0.28 | $-0.11 | ||
| Q1 25 | $0.30 | $0.14 | ||
| Q4 24 | $0.33 | $0.22 | ||
| Q3 24 | $0.20 | $0.21 | ||
| Q2 24 | $0.25 | $0.26 | ||
| Q1 24 | $0.30 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $108.5M | $172.9M |
| Total DebtLower is stronger | $5.1B | $260.0M |
| Stockholders' EquityBook value | $7.0B | $2.0B |
| Total Assets | $13.2B | $2.5B |
| Debt / EquityLower = less leverage | 0.72× | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $108.5M | $172.9M | ||
| Q3 25 | $45.6M | — | ||
| Q2 25 | $323.3M | $162.2M | ||
| Q1 25 | $69.7M | $140.7M | ||
| Q4 24 | $199.4M | $177.5M | ||
| Q3 24 | $162.5M | $187.5M | ||
| Q2 24 | $718.4M | $152.9M | ||
| Q1 24 | $124.8M | $145.3M |
| Q4 25 | $5.1B | $260.0M | ||
| Q3 25 | $4.8B | — | ||
| Q2 25 | $5.2B | $346.0M | ||
| Q1 25 | $4.9B | $330.0M | ||
| Q4 24 | $5.0B | $300.0M | ||
| Q3 24 | $4.5B | $300.0M | ||
| Q2 24 | $5.0B | $319.0M | ||
| Q1 24 | $4.5B | $389.0M |
| Q4 25 | $7.0B | $2.0B | ||
| Q3 25 | $7.2B | — | ||
| Q2 25 | $7.2B | $1.9B | ||
| Q1 25 | $7.2B | $2.0B | ||
| Q4 24 | $7.2B | $2.1B | ||
| Q3 24 | $7.0B | $2.1B | ||
| Q2 24 | $7.0B | $2.1B | ||
| Q1 24 | $7.0B | $2.0B |
| Q4 25 | $13.2B | $2.5B | ||
| Q3 25 | $13.3B | — | ||
| Q2 25 | $13.6B | $2.6B | ||
| Q1 25 | $13.3B | $2.6B | ||
| Q4 24 | $13.4B | $2.7B | ||
| Q3 24 | $12.8B | $2.7B | ||
| Q2 24 | $13.3B | $2.7B | ||
| Q1 24 | $12.8B | $2.7B |
| Q4 25 | 0.72× | 0.13× | ||
| Q3 25 | 0.68× | — | ||
| Q2 25 | 0.72× | 0.18× | ||
| Q1 25 | 0.69× | 0.16× | ||
| Q4 24 | 0.70× | 0.14× | ||
| Q3 24 | 0.64× | 0.14× | ||
| Q2 24 | 0.71× | 0.15× | ||
| Q1 24 | 0.64× | 0.19× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $864.3M | — |
| Free Cash FlowOCF − Capex | $823.7M | — |
| FCF MarginFCF / Revenue | 181.0% | — |
| Capex IntensityCapex / Revenue | 8.9% | — |
| Cash ConversionOCF / Net Profit | 5.99× | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.5B | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $864.3M | — | ||
| Q3 25 | $223.3M | — | ||
| Q2 25 | $271.9M | $98.2M | ||
| Q1 25 | $223.4M | $41.1M | ||
| Q4 24 | $811.5M | $84.3M | ||
| Q3 24 | $233.6M | $63.9M | ||
| Q2 24 | $274.0M | $75.5M | ||
| Q1 24 | $201.8M | $81.0M |
| Q4 25 | $823.7M | — | ||
| Q3 25 | $214.5M | — | ||
| Q2 25 | $257.7M | $93.3M | ||
| Q1 25 | $215.9M | $31.0M | ||
| Q4 24 | $777.5M | $77.5M | ||
| Q3 24 | $225.3M | $54.7M | ||
| Q2 24 | $263.3M | $57.5M | ||
| Q1 24 | $191.0M | $64.5M |
| Q4 25 | 181.0% | — | ||
| Q3 25 | 44.8% | — | ||
| Q2 25 | 56.3% | 29.4% | ||
| Q1 25 | 47.0% | 9.8% | ||
| Q4 24 | 178.1% | 26.1% | ||
| Q3 24 | 50.6% | 18.9% | ||
| Q2 24 | 62.2% | 18.8% | ||
| Q1 24 | 45.1% | 21.3% |
| Q4 25 | 8.9% | — | ||
| Q3 25 | 1.8% | — | ||
| Q2 25 | 3.1% | 1.5% | ||
| Q1 25 | 1.6% | 3.2% | ||
| Q4 24 | 7.8% | 2.3% | ||
| Q3 24 | 1.9% | 3.2% | ||
| Q2 24 | 2.5% | 5.9% | ||
| Q1 24 | 2.6% | 5.4% |
| Q4 25 | 5.99× | — | ||
| Q3 25 | 1.91× | — | ||
| Q2 25 | 2.20× | — | ||
| Q1 25 | 1.74× | 1.82× | ||
| Q4 24 | 5.64× | 2.42× | ||
| Q3 24 | 2.67× | 1.90× | ||
| Q2 24 | 2.52× | 1.86× | ||
| Q1 24 | 1.58× | 1.65× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMH
Segment breakdown not available.
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
